同和药业
(300636)
| 流通市值：37.87亿 | | | 总市值：43.96亿 |
| 流通股本：3.64亿 | | | 总股本：4.23亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 206,454,983.02 | 722,138,705.43 | 559,661,869.75 | 381,754,020.7 |
| 营业收入 | 206,454,983.02 | 722,138,705.43 | 559,661,869.75 | 381,754,020.7 |
| 二、营业总成本 | 150,662,133.88 | 599,899,694.96 | 476,319,761.9 | 326,536,126.62 |
| 营业成本 | 130,754,859.21 | 481,658,031.74 | 384,565,908.15 | 254,500,727.9 |
| 税金及附加 | 859,073.9 | 3,663,137.67 | 2,802,759.71 | 1,745,553.6 |
| 销售费用 | 5,925,788.93 | 26,255,096.1 | 17,560,749.16 | 11,836,681.67 |
| 管理费用 | 8,397,949.83 | 34,570,543.15 | 27,957,757.43 | 19,049,478.94 |
| 研发费用 | 10,292,403.05 | 63,151,225.15 | 47,477,333.47 | 38,528,583.21 |
| 财务费用 | -5,567,941.04 | -9,398,338.85 | -4,044,746.02 | 875,101.3 |
| 其中:利息费用 | 4,062,134.72 | 9,895,391.93 | 6,165,689.38 | 4,411,437.9 |
| 其中:利息收入 | 9,013,826.29 | 17,010,576.73 | 8,903,755.73 | 2,739,527.79 |
| 加:投资收益 | - | 567,878.95 | - | - |
| 资产处置收益 | 0 | -1,320,772.82 | -888,311.39 | - |
| 资产减值损失(新) | -7,920,742.47 | -19,143,082.69 | -993,638.13 | -2,496,449.33 |
| 信用减值损失(新) | -2,525,755.02 | 107,338.4 | -1,472,674.43 | -404,710.31 |
| 其他收益 | 3,685,602.25 | 9,781,885.63 | 9,231,914.65 | 8,816,742 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 49,031,953.9 | 112,232,257.94 | 89,219,398.55 | 61,133,476.44 |
| 加:营业外收入 | 0 | 354,079.9 | 6,725.66 | 6,725.66 |
| 减:营业外支出 | 66,750 | 85,990 | 65,990 | 65,990 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 48,965,203.9 | 112,500,347.84 | 89,160,134.21 | 61,074,212.1 |
| 减:所得税费用 | 5,402,452.76 | 6,517,090.69 | 10,506,966.35 | 4,043,379.39 |
| 六、净利润 | 43,562,751.14 | 105,983,257.15 | 78,653,167.86 | 57,030,832.71 |
| 持续经营净利润 | - | 105,983,257.15 | 78,653,167.86 | 57,030,832.71 |
| 归属于母公司股东的净利润 | 43,562,751.14 | 105,983,257.15 | 78,653,167.86 | 57,030,832.71 |
| (一)基本每股收益 | 0.1 | 0.28 | 0.21 | 0.16 |
| (二)稀释每股收益 | 0.1 | 0.28 | 0.21 | 0.16 |
| 九、综合收益总额 | 43,562,751.14 | 105,983,257.15 | 78,653,167.86 | 57,030,832.71 |
| 归属于母公司股东的综合收益总额 | 43,562,751.14 | 105,983,257.15 | 78,653,167.86 | 57,030,832.71 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-26 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |